

Table 7 What is considered to be important when selecting Kampo medicine for prescription

Concerns	All (n=200)		Palliative care team(n=149)		PCU(n=46)		p-value	Specialists(n=75)		non-specialists(n=125)		p-value
	frequency	%	frequency	%	frequency	%		frequency	%	frequency	%	
Symptom-alleviating effects (alleviation of adverse events)	173	93.0	135	90.6	36	78.3	0.017	64	85.3	109	87.2	0.248
Alleviation of symptoms which reduce QOL in the terminal stage of cancer	162	87.6	127	85.2	34	73.9	0.003	60	80.0	102	81.6	0.647
Low incidence of adverse events	157	84.9	122	81.9	34	73.9	0.020	62	82.7	95	76.0	0.299
Easy to combine with other drugs	149	80.5	117	78.5	30	65.2	0.206	57	76.0	92	73.6	1.000
Long-lasting effects	124	68.1	102	68.5	21	45.7	0.009	47	62.7	77	61.6	0.871
Scientific evidences	114	61.6	85	57.0	27	58.7	0.938	45	60.0	69	55.2	0.641
Cheap drug prices	105	57.4	81	54.4	23	50.0	0.647	42	56.0	63	50.4	0.645
Described in the guidelines	97	53.0	73	49.0	23	50.0	0.791	35	46.7	62	49.6	0.545
Patient's demand	95	51.9	68	45.6	25	54.3	0.439	43	57.3	52	41.6	0.049
Efficacy can be investigated with large-scale clinical trials	94	51.1	71	47.7	22	47.8	0.894	37	49.3	57	45.6	0.762
Contribute to the accomplishment of chemotherapy	90	49.2	74	49.7	14	30.4	0.070	35	46.7	55	44.0	0.762
Effects manifest itself quickly	88	47.8	67	45.0	20	43.5	0.946	36	48.0	52	41.6	0.548

*Multiple answers allowed